Revvity (RVTY) Short-term Investments (2023 - 2024)
Revvity's (RVTY) quarterly Short-term Investments came in at $706.1 million in Q2 2024, down 4.46% on a YoY basis from $739.1 million in Q3 2023, and up 1.25% quarter-over-quarter from $697.3 million in Q1 2024.
Powered by 
Analysis
Revvity (RVTY) Short-term Investments (2023 - 2024) Analysis & Trends
Revvity (RVTY) has reported Short-term Investments for 2 consecutive years, with $706.1 million the latest figure, recorded in Q2 2024.
- For the quarter ending Q2 2024, Short-term Investments fell 4.46% year-over-year to $706.1 million; the trailing twelve-month figure through Jun 2024 stood at $706.1 million (down 4.46% YoY), and the FY2023 full-year result was $689.9 million, changed N/A from the prior year.
- Short-term Investments climbed to $706.1 million in Q2 2024 per RVTY's latest filing, from $697.3 million in the prior quarter.
- Across five years, Short-term Investments topped out at $739.1 million in Q3 2023 and bottomed at $194.0 million in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 241.68 Bn | 237.61 Bn | 8.34 Bn |
| 2 | Danaher | 147.34 Bn | 142.99 Bn | 3.61 Bn |
| 3 | Agilent Technologies | 43.34 Bn | 41.59 Bn | 1.04 Bn |
| 4 | Illumina | 34.58 Bn | 33.41 Bn | 770.00 Mn |
| 5 | Revvity | 16.31 Bn | 15.29 Bn | 416.87 Mn |
| 6 | Bio-Techne | 11.28 Bn | 11.01 Bn | 211.39 Mn |
| 7 | Bio-Rad Laboratories | 10.16 Bn | 8.54 Bn | 345.80 Mn |
| 8 | Repligen | 9.77 Bn | 8.75 Bn | 110.04 Mn |
| 9 | 10x Genomics | 9.45 Bn | 8.90 Bn | 112.50 Mn |
| 10 | Bruker | 9.26 Bn | 9.04 Bn | 416.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 706.07 Mn |
| Mar 31, 2024 | 697.33 Mn |
| Dec 31, 2023 | 689.92 Mn |
| Oct 1, 2023 | 292.97 Mn |
| Jul 2, 2023 | 739.06 Mn |
| Apr 2, 2023 | 193.96 Mn |